Back to Search
Start Over
Predictors of bowel damage in the long-term progression of Crohn's disease.
- Source :
-
World journal of clinical cases [World J Clin Cases] 2022 Nov 26; Vol. 10 (33), pp. 12208-12220. - Publication Year :
- 2022
-
Abstract
- Background: Crohn's disease (CD) is a chronic inflammatory bowel disorder that progresses to bowel damage (BD) over time. An image-based index, the Lémann index (LI), has been developed to measure cumulative BD.<br />Aim: To characterize the long-term progression of BD in CD based on changes in the LI and to determine risk factors for long-term progression.<br />Methods: This was a single-center longitudinal cohort study. Patients who had participated in prospective studies on the accuracy of magnetic resonance imaging using endoscopy as a gold standard and who had a follow-up of at least 5 years were re-evaluated after 5-12 years.<br />Results: Seventy-two patients were included. LI increased in 38 patients (52.8%), remained unchanged in 9 patients (12.5%), and decreased in 25 patients (34.7%). The small bowel score and surgery subscale significantly increased ( P = 0.002 and P = 0.001, respectively), whereas the fistulizing subscale significantly decreased ( P = 0.001). Baseline parameters associated with BD progression were ileal location ( P = 0.026), CD phenotype [stricturing, fistulizing, or both ( P = 0.007, P = 0.006, and P = 0.035, respectively)], disease duration > 10 years ( P = 0.019), and baseline LI stricturing score ( P = 0.049). No correlation was observed between BD progression and baseline clinical activity, biological markers, or severity of endoscopic lesions.<br />Conclusion: BD, as assessed by the LI, progressed in half of the patients with CD over a period of 5-12 years. The main determinants of BD progression were ileal location, stricturing/fistulizing phenotype, and disease duration.<br />Competing Interests: Conflict-of-interest statement: Dr. Rimola reports grants from Abbvie, personal fees from Alimentiv, personal fees from Janssen, personal fees from Takeda, non-financial support from Gilead and from Agumab during the conduct of the study.<br /> (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2307-8960
- Volume :
- 10
- Issue :
- 33
- Database :
- MEDLINE
- Journal :
- World journal of clinical cases
- Publication Type :
- Academic Journal
- Accession number :
- 36483818
- Full Text :
- https://doi.org/10.12998/wjcc.v10.i33.12208